DGIdb - ERYTHROMYCIN Drug Record

ERYTHROMYCIN chembl:CHEMBL532 Approved

Alternate Names:

NSC-55929
E-GLADES
ERYC
PAEDIATHROCIN
ERYGEL
E-SOLVE 2
E-MYCIN
ERYDERM
A/T/S
C-SOLVE-2
J01FA01
OFTALMOLOSA CUSI ERITROMICINA
WYAMYCIN
STIEMYCIN
ERYTHROCIN
KERYMAX
ZINERYT
SANSAC
AKNEMYCIN PLUS
ERYACNE 2
ERYMAX
STATICIN
EMGEL
ERYACNE 4
R-P MYCIN
AKNE-MYCIN
ERY-TAB
BRISTAMYCIN
ROMMIX 250 EC
ROBIMYCIN
ERYTHRO 200
ERYPAR
ERYC 125
ERYC SPRINKLES
ERYTHROMYCIN
ERYCETTE
ERYTHRO-STATIN
TILORYTH
ERYTHRA-DERM
ILOTYCIN
PCE
GALLIMYCIN
T-STAT
ROMMIX 500 EC
ERYMAX SPRINKLE
RETCIN
E-BASE
PFIZER-E
BENZAMYCIN
ISOTREXIN
ÉRYTHROMYCINE
(2R,4S,5R,8R,12R,14R)-11-[(3R,4S,6R)-4-(DIMETHYLAMINO)-3-HYDROXY-6-METHYL-OXAN-2-YL]OXY-5-ETHYL-3,4,12-TRIHYDROXY-9-[(2R,4R,5S,6S)-5-HYDROXY-4-METHOXY-4,6-DIMETHYL-OXAN-2-YL]OXY-2,4,8,10,12,14-HEXAMETHYL-6-OXACYCLOTETRADECANE-1,7-DIONE
6-(4-DIMETHYLAMINO-3-HYDROXY-6-METHYL-TETRAHYDRO-PYRAN-2-YLOXY)-14-ETHYL-7,12,13-TRIHYDROXY-4-(5-HYDROXY-4-METHOXY-4,6-DIMETHYL-TETRAHYDRO-PYRAN-2-YLOXY)-3,5,7,9,11,13-HEXAMETHYL-OXACYCLOTETRADECANE-2,10-DIONE(ERYTHROMYCIN)
ERYTHROMYCIN A
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(4-DIMETHYLAMINO-3-HYDROXY-6-METHYL-TETRAHYDRO-PYRAN-2-YLOXY)-14-ETHYL-7,12,13-TRIHYDROXY-4-(5-HYDROXY-4-METHOXY-4,6-DIMETHYL-TETRAHYDRO-PYRAN-2-YLOXY)-3,5,7,9,11,13-HEXAMETHYL-OXACYCLOTETRADECANE-2,10-DIONE
ERYTHROMYCINUM
ERITROMICINA
ERYTHROMYCIN C
ABOMACETIN
ERTHROMYCIN
3''-O-DEMETHYLERYTHROMYCIN
(2R,4S,5R,8R,12R,14R)-11-[(3R,4S,6R)-4-(DIMETHYLAMINO)-3-HYDROXY-6-METHYLOXAN-2-YL]OXY-5-ETHYL-3,4,12-TRIHYDROXY-9-[(2R,4R,5S,6S)-5-HYDROXY-4-METHOXY-4,6-DIMETHYLOXAN-2-YL]OXY-2,4,8,10,12,14-HEXAMETHYL-6-OXACYCLOTETRADECANE-1,7-DIONE
ERYTHROMYCINE
rxcui:4053
chemidplus:114-07-8
drugbank:00199
chembl:CHEMBL532
pubchem.compound:12560

Drug Info:

(3 More Sources)

Publications:

Tsuda et al., 2008, Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes., Antimicrob. Agents Chemother.
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Xu et al., 2006, [Effect of erythromycin on apoptosis of epithelial cell in nasal polyps]., Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
Takeshita et al., 1989, Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages., Drugs Exp Clin Res
Terashi et al., 2000, Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells., Antimicrob. Agents Chemother.
Volberg et al., 2002, Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics., J. Pharmacol. Exp. Ther.
Stanat et al., 2003, Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel., Mol. Cell. Biochem.
Du et al., 2004, The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents., Bioorg. Med. Chem. Lett.
Wisialowski T et al., 2006, Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability., J Pharmacol Exp Ther
Crumb WJ Jr, 2014, Allosteric effects of erythromycin pretreatment on thioridazine block of hERG potassium channels., Br J Pharmacol
Deloose et al., 2016, The motilin receptor agonist erythromycin stimulates hunger and food intake through a cholinergic pathway., Am. J. Clin. Nutr.
Peeters et al., 1989, Erythromycin is a motilin receptor agonist., Am. J. Physiol.
Vanaudenaerde et al., 2007, Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells., Am. J. Transplant.
Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
Elens L et al., 2013, CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin., Pharmacogenomics
Li P et al., 2011, A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors., Drug Metab Dispos
Aktan et al., Effect of macrolide antibiotics on nitric oxide synthase and xanthine oxidase activities, and malondialdehyde level in erythrocyte of the guinea pigs with experimental otitis media with effusion., Pol J Pharmacol
Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem

ERYTHROMYCIN MLNR

Interaction Score: 1.2

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

PMIDs:
26817505 2782416

Sources:
GuideToPharmacology
ERYTHROMYCIN F2RL1

Interaction Score: 0.71

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18212111

Sources:
DTC
ERYTHROMYCIN IL17A

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17061983

Sources:
NCI
ERYTHROMYCIN XDH

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14730107

Sources:
NCI
ERYTHROMYCIN IL1B

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2534682

Sources:
NCI
ERYTHROMYCIN BCL2

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17007374

Sources:
NCI
ERYTHROMYCIN BAX

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17007374

Sources:
NCI
ERYTHROMYCIN ABCC1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10817732

Sources:
NCI
ERYTHROMYCIN CYP3A5

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
ERYTHROMYCIN ABCC2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ERYTHROMYCIN KCNH2

Interaction Score: 0.06

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
12065733 14674677 15324906 16614168 24417241

Sources:
PharmGKB
ERYTHROMYCIN G6PD

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Combination therapy Erythromycin,Sulfisoxazole

PMIDs:
None found

Sources:
FDA
ERYTHROMYCIN NR1I2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ERYTHROMYCIN PLK1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ERYTHROMYCIN CYP3A4

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9187528 23327575 21393461

Sources:
DTC PharmGKB
ERYTHROMYCIN CYP2C9

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
ERYTHROMYCIN CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
ERYTHROMYCIN ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ERYTHROMYCIN CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
ERYTHROMYCIN CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC

DTC: ERYTHROMYCIN

Version: 02-September-2020

Alternate Names:

CHEMBL532 ChEMBL Drug ID

Drug Info:

Publications:

Tsuda et al., 2008, Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes., Antimicrob. Agents Chemother.

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Li P et al., 2011, A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors., Drug Metab Dispos

NCI: ERYTHROMYCIN

Version: 14-September-2017

Alternate Names:

C476 NCI drug code

Drug Info:

Publications:

Takeshita et al., 1989, Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages., Drugs Exp Clin Res

Vanaudenaerde et al., 2007, Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells., Am. J. Transplant.

Xu et al., 2006, [Effect of erythromycin on apoptosis of epithelial cell in nasal polyps]., Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi

PharmGKB: erythromycin

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem

Wisialowski T et al., 2006, Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability., J Pharmacol Exp Ther

Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev

GuideToPharmacology: 135652682
- Version: 29-September-2020
Alternate Names:

ERYTHROMYCIN GuideToPharmacology Ligand Name

Drug Info:

Publications:
TTD: Erythromycin
- Version: 2020.06.01
Alternate Names:

D02YIZ TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL532
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Erythromycin
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Specific Action of the Ligand	Full agonist
Endogenous Drug?	False

ERYTHROMYCIN Drug Record

ERYTHROMYCIN chembl:CHEMBL532 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: agonist (activating)

Interaction Info: Specific Action of the Ligand Full agonist Endogenous Drug? False

PMIDs: 26817505 2782416

Sources: GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18212111

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17061983

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14730107

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 2534682

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17007374

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17007374

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10817732

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18695978

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 12065733 14674677 15324906 16614168 24417241

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Combination therapy Erythromycin,Sulfisoxazole

PMIDs: None found

Sources: FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9187528 23327575 21393461

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

PMIDs:
26817505 2782416

Sources:
GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
18212111

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
17061983

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14730107

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
2534682

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17007374

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17007374

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10817732

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
12065733 14674677 15324906 16614168 24417241

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Combination therapy Erythromycin,Sulfisoxazole

PMIDs:
None found

Sources:
FDA

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
9187528 23327575 21393461

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Alternate Names:

CHEMBL532 ChEMBL Drug ID

Alternate Names:

C476 NCI drug code

Alternate Names:

ERYTHROMYCIN GuideToPharmacology Ligand Name

Alternate Names:

D02YIZ TTD Drug ID